WAINUA (AUTOINJECTOR)

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
  Ulefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic…
  biospace · 15d ago
• 5 biotechs braving the commercial waters with product launches
  A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.
  biospace · 22d ago
• Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
  After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-profile…
  biospace · 1mo ago
• Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
  Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbrea…
  biospace · 1mo ago
• STAT+: Trump strikes nine more deals with drugmakers to lower prices
  President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.
  stat · 1mo ago
• ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
  As AstraZeneca appears to close the book on a combo approach following the phase 3 failure of its Ionis-partnered Wainua, several analysts contend it’s too early to count out Alnylam’s silencing dr…
  fiercebiotech · 1mo ago
• STAT+: Can a pregnancy hormone steer a cardiovascular treatment?
  Caution and survival in radiopharmaceuticals, mRNA skepticism, and more biotech news from The Readout
  stat · 1mo ago
• STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy
  Researchers believe radiopharmaceuticals have great promise as cancer treatments. But are they using them too timidly?
  stat · 1mo ago
• STAT+: After a rough stretch, mRNA gets a boost — at least for now
  With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the technology in other areas.
  stat · 1mo ago
• STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer
  Mimrylo, from Takeda and Protagonist, is a new kind of treatment for the blood cancer polycythemia vera.
  stat · 1mo ago